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Abstract
An important component of the pathologic process underlying Alzheimer’s disease (AD) is
oxidative stress. Met35 in amyloid β-protein (Aβ) is prone to participating in redox reactions
promoting oxidative stress, and therefore is believed to contribute significantly Aβ-induced
toxicity. Thus, substitution of Met35 by residues that do not participate in redox chemistry would
be expected to decrease Aβ toxicity. Indeed, substitution of Met35 by norleucine (Nle) was
reported to reduce Aβ toxicity. Surprisingly, however, substitution of Met35 by Val was reported
to increase toxicity. Aβ toxicity is known to be strongly related to its self-assembly. However,
neither substitution is predicted to affect Aβ assembly substantially. Thus, the effect of these
substitutions on toxicity is difficult to explain. We revisited this issue and compared Aβ40 and
Aβ42 with analogues containing Met35→Nle or Met35→Val substitutions using multiple
biophysical and toxicity assays. We found that substitution of Met35 by Nle or Val had moderate
effects on Aβ assembly. Surprisingly, despite these effects, neither substitution changed Aβ
neurotoxicity significantly in three different assays. These results suggest that the presence of
Met35 in Aβ is not important for Aβ toxicity, challenging to the prevailing paradigm, which
suggests that redox reactions involving Met35 contribute substantially to Aβ-induced toxicity.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive, age-related neurodegenerative disorder, which
gradually impairs cognitive abilities, causes difficulties in execution of routine tasks, and
finally leads to dementia and death (Selkoe 2001, Cummings 2004). Amyloid plaques,
neurofibrillary tangles, neurite dystrophy, synapse loss, and neurodegeneration in the
cerebral cortex and hippocampus are pathologic hallmarks of AD (Selkoe 2001). Genetic,
physiologic, and biochemical data indicate that self-assembly of amyloid β-protein (Aβ)
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initiates the disruption of interneuronal communication in AD (Roher et al. 1993, Hardy &
Selkoe 2002, Roychaudhuri et al. 2009). Though initially Aβ fibrils, the predominant
component of amyloid plaques, were thought to be the culprit, now soluble Aβ oligomers
are believed to be the major neurotoxic species in AD (Dahlgren et al. 2002, White et al.
2005, Haass & Selkoe 2007, Tomic et al. 2009). Plaque formation is thought be an attempt
of the brain to sequester the toxic oligomers in a less harmful fibrillar structure (Bravo et al.
2008, Josephs et al. 2008, Reiman et al. 2009), though plaques also may serve as reservoirs
of oligomeric Aβ (Koffie et al. 2009).
The C-terminal region of Aβ plays a key role in controlling Aβ oligomerization and
aggregation (Bitan et al. 2003a, Jarrett et al. 1993, Bitan et al. 2003c). Within this region,
oxidation of Met35 to sulfoxide has been reported to alter substantially Aβ oligomerization
(Palmblad et al. 2002, Hou et al. 2002, Hou et al. 2004, Bitan et al. 2003b) and
neurotoxicity (Varadarajan et al. 1999, Varadarajan et al. 2001, Varadarajan et al. 2000,
Barnham et al. 2003, Ciccotosto et al. 2004). The sulfoxide form of Aβ has been found in
cerebral tissue extracts derived from patients with AD and transgenic mice (Kuo et al. 2001,
Näslund et al. 1994). Whether these findings point to a causative effect of oxidation of Aβ to
the sulfoxide in AD or are merely a result of the oxidative environment in the AD brain, or a
protein-extraction-induced artifact, is an open question.
Redox reactions in the AD brain generate highly reactive free radicals (Butterfield 2002,
Halliwell 2006). To regain stability, these radicals abstract electrons or hydrogen atoms
from neighboring molecules or groups, leading to perturbation of the chemical structure, and
destruction of biological molecules (Butterfield et al. 2007). Free radicals normally form in
a controlled manner in the mitochondrial respiratory chain during oxidative phosphorylation
when molecular oxygen is reduced to water (Halliwell 2006). During this process, two
reactive oxygen species (ROS) form: superoxide anion (O2−) and hydrogen peroxide
(H2O2). In addition, O2− or H2O2 may be generated by multiple other enzymatic and non-
enzymatic cellular mechanisms (Halliwell 1989). H2O2 may further form hydroxyl radicals
(OH•) via Fenton chemistry (Halliwell 2006, Markesbery & Lovell 1998). When the control
mechanisms that maintain these and other ROS are compromised, as happens in AD, the
result is oxidative damage, including lipid peroxidation, protein carbonylation, and other
modifications of essential biomolecules (Crouch et al. 2008, Markesbery & Lovell 1998,
Halliwell 2006, Butterfield et al. 2007).
Under the highly oxidative environment in the AD brain, oxidation of Met35 in Aβ may lead
to formation of Met-sulfuranyl radicals (MetS•), which may initiate, or participate in, the
destructive chemistry described above. Thus, oxidation of Met35 in Aβ has been postulated
to be directly involved in Aβ toxicity. Alternatively, neurotoxic mechanisms caused by Aβ
oligomers, including disruption of Ca2+ homeostasis and excitotoxicity (Piacentini et al.
2008), may cause oxidative stress that would, among other things, oxidize Met35 in Aβ, as a
result, not cause, of Aβ toxicity.
If Met35 oxidation causes Aβ toxicity, substitution of Met35 by aliphatic residues that lack
sulfur, do not form radicals easily, and are not substrate for ROS, would be expected to
suppress Aβ toxicity. In line with this hypothesis, substitution of Met35 by Nle has been
reported to decrease Aβ toxicity (Varadarajan et al. 1999, Butterfield & Kanski 2002,
Clementi et al. 2006, Yatin et al. 1999). Surprisingly, however, substitution of Met35 by Val
had the opposite effect (Ciccotosto et al. 2004). Complicating matters further, Ciccotosto et
al reported that [Val35]Aβ42 produces similar amounts of H2O2 as Aβ42, whereas Murray et
al. found that [Val35]Aβ42 showed reduced lipid peroxidation relative to Aβ42 (Murray et
al. 2005).
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Because Met35 resides in the middle of the hydrophobic C-terminus of Aβ, and because Met,
Nle, and Val all are hydrophobic residues, the Met35→Nle or Met35→Val substitutions are
not expected to have a strong effect on Aβ assembly. Indeed, substitution of Met35 by Nle
had little effect on the oligomer size distribution of Aβ (Bitan et al. 2003b).
Because substantial efforts have been dedicated to understanding the role of Met35 in Aβ in
AD, we felt that the discrepancy between previous studies using similar strategies to answer
the same question merited a re-examination. Here, we addressed this discrepancy by
investigating the effect of substituting Met35 in Aβ40 and Aβ42 by either Nle or Val. We
describe a systematic, side-by-side comparison of each substituted Aβ analogue using assays
for oligomer size distribution, conformational change, assembly size, fibril morphology, and
toxicity in primary neurons.
MATERIALS AND METHODS
Chemicals and supplies
Silver-staining kit, 10–20% gradient Tris-tricine gels, penicillin/streptomycin, and APO-
BrdU Apoptosis Detection kit were purchased from Invitrogen (Carlsbad, CA). Tris(2,2’-
bipyridyl)ruthenium dichloride (Ru(Bpy)), ammonium persulfate, glutaraldehyde, uranyl
acetate, cytosine arabinofuranoside, and poly D-lysine were from Sigma (St. Louis, MO).
1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) was from TCI America (Portland, OR). Trypsin-
EDTA solution, Dulbecco’s Modified Eagle’s Medium (DMEM), Leibovitz L15 medium,
and fetal bovine serum were from ATCC (Manassas, VA). Electron microscopy (EM) grids
were purchased from Electron Microscopy Science (Hatfield, PA). Cover slips and 96-well
black and white plates were from Fisher scientific (Tustin, CA). CytoTox-ONE™
Homogeneous Membrane Integrity Assay kits and 2,5-diphenyltetrazolium bromide were
from Promega (Madison, WI).
Animals
All experiments were performed in accordance with the National Research Council Guide
for the Care and Use of Laboratory Animals and were approved by the UCLA Institutional
Animal Care Use Committee. Pregnant, E18, Sprague-Dawley rats were purchased from
Charles River laboratory (Wilmington, MA).
Peptides synthesis
Aβ40, [Nle35]Aβ40, [Val35]Aβ40, Aβ42, [Nle35]Aβ42, and [Val35]Aβ42 were synthesized,
purified and characterized by the UCLA Biopolymers Laboratory as described previously
(Lomakin et al. 1996). Briefly, peptides were synthesized on an automated peptide
synthesizer (Model 433A, Applied Biosystems, Foster City, CA) using 9-
fluorenylmethoxycarbonyl chemistry and purified by reverse-phase high-performance liquid
chromatography (HPLC). Quantitative amino acid analysis and mass spectrometry were
used to characterize the expected compositions and molecular masses, respectively, for each
peptide.
Preparation of peptide solutions
Purified peptides were stored as lyophilized powders at −20°C. Before use, peptides were
treated with HFIP and stored as dry films at −20°C as described previously (Rahimi et al.
2009). For biophysical measurements, immediately before use, films were dissolved in 60
mM NaOH at 10% of the desired volume. The solution then was diluted to 50% of the
desired volume with deionized water (18.2 MΩ produced by a Milli-Q system, Millipore,
Bedford, MA) and sonicated for 1 min. Then, the solution was diluted with 20 mM sodium
phosphate, pH 7.4, to the final peptide concentration, which was 10 µM unless stated
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otherwise. For toxicity experiments, peptides were diluted with cell-culture media after
initial dissolution in 10% NaOH, and then sonicated for 1 min.
Photo-cross-linking and SDS-PAGE analysis
The experimental protocol was described previously (Rahimi et al. 2009, Vollers et al. 2005,
Bitan 2006). Briefly, peptide solutions were centrifuged at 14,000 g for 10 min. The
supernates were subjected to Photo-Induced Cross-linking of Unmodified Proteins (PICUP)
(Fancy & Kodadek 1999). For each cross-linking reaction, 2 µl of 1 mM Ru(Bpy) and 2 µl
of 20 mM ammonium persulfate (APS) were added to 18 µl of peptide solution. The
mixtures were irradiated with visible light for 1 s and the reaction was quenched
immediately with 10 µl of Tricine sample buffer (Invitrogen) containing 5% β-
mercaptoethanol. The cross-linked peptides were boiled for 5 min and analyzed by SDS-
PAGE, silver stained, and subjected to densitometric analysis using Image J (NIH software,
http://rsb.info.nih.gov). The data are an average of six independent experiments.
Circular dichroism spectroscopy (CD)
Samples were incubated at 25°C with continuous agitation using an orbital shaker at 200
rpm. Spectra were recorded every 2 h during the first 12 h, and then at 24, 48, and 72 h,
using a J-810 spectropolarimeter (Jasco, Easton, MD) equipped with a thermostable sample
cell at 25°C using 1-mm path-length cuvettes. Spectra were collected from 190–260 nm with
1-s response time, 50-nm/min scan speed, 0.2-nm resolution and 2-nm bandwidth, and
averaged after background subtraction. The data are representative of three independent
experiments.
Dynamic light scattering (DLS)
Samples prepared as described above, filtered immediately before the first measurement
through 20-nm cutoff, Anotop filters (Whatman, Florham Park, NJ), and incubated at room
temperature without agitation. Measurements were performed using an in-house-built
system with a He-Ne laser model 127 (wavelength 633 nm, power 60 mW, Spectra Physics
lasers, Mountain View, CA). Light scattered at 90° was collected using image transfer optics
and detected by an avalanche photodiode built into a PD4047 multitau correlator (Precision
Detectors, Bellingham, MA). The size distribution of scattering particles was reconstructed
from the correlation function of the scattered light using PrecisionDeconvolve (Precision
Detectors) based on the regularization method by Tikhonov and Arsenin (Tikhonov, 1977).
The data are representative of two independent experiments.
Electron microscopy (EM)
Samples were incubated at 25°C with continuous agitation using an orbital shaker at 200
rpm. Eight-µl aliquots were applied to glow-discharged, carbon-coated Formvar grids for 20
min. The solution was wicked gently with filter paper. Then the samples were fixed with 5
µl of 2.5% glutaraldehyde for 4 min and stained with 5 µl of 1% uranyl acetate for 3 min.
The solution was wicked off and the grids were air-dried. The morphology was visualized
using a CM120 (FEI, Philips) transmission electron microscope.
Cell culture
Primary neurons were prepared from E18 rat embryos as described previously (Segal &
Manor 1992). Briefly, E18 pregnant rats were euthanized with CO2 and the pups were
collected immediately. The brains were dissected in chilled Leibovitz’s L15 medium in the
presence of penicillin/streptomycin (1 µg/ml). The tissue was incubated with 0.25% trypsin-
EDTA solution for 30 min and then mechanically dissociated in a small volume of
Leibovitz’s L15 media using a fire-polished Pasteur pipette. The cells were suspended in
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DMEM containing 10% heat-inactivated fetal bovine serum and penicillin/streptomycin (1
µg/ml), and plated in poly D-lysine (0.1 mg %)-coated 96-well plates (COSTAR, Corning,
USA) at a density of 3×105 cells/ml. The cultures were maintained at 37°C in a humidified
atmosphere of 5% CO2 for 6 d before treatment with peptides. Twenty-four hours after
plating, the medium was replaced with fresh medium supplemented with 5 µM cytosine β-
D-arabinofuranoside to inhibit the proliferation of glial cells.
MTT assay
Cells were treated with freshly prepared Aβ analogues for 48 h. Cell viability was measured
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell-
metabolism assay, as described previously (Fradinger et al. 2008). Briefly, following
treatment, 15 µl of MTT were added to each well and incubated for 4 h at 37°C. Then, stop
solution was added and kept overnight at room temperature. The OD was measured using a
Synergy plate reader (Bio-TEK instruments, Winooski, VT). The cell viability results of
three independent experiments (6 wells per condition) were normalized to the medium
control group and expressed as mean ± SEM.
LDH assay
Neurons were incubated with freshly prepared Aβ analogues for 48 h and cell death was
assayed by measuring the release of lactate dehydrogenase (LDH) using CytoTox-ONE™
Homogeneous Membrane Integrity Assay kit (Promega) according to the manufacturer’s
instructions. Data from three independent experiments (6 wells per condition) were
normalized to medium control and expressed as mean ± SEM.
TUNEL assay
Neurons were grown on poly D-lysine-coated cover slips and treated with freshly prepared
Aβ analogues for 48 h. The cells were then washed with phosphate-buffered saline (PBS)
and fixed with 4% paraformaldehyde. Cover slips then were treated with ethanol for 30 min
at −20°C, followed by 3×5 min washes with the “wash buffer” supplied in the kit, and
incubated with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
DNA labeling solution for 1 h at 37°C. The cells were washed and treated with an anti-BrdU
antibody for 30 min at room temperature in the dark. Cover slips then were washed with the
“rinse buffer” supplied in the kit and counter-stained with 1% propidium iodide for 15 min
in the dark, washed with deionized water, dehydrated, cleared, and mounted on glass slides
using glycerol. Fluorescent signals were visualized using a Nikon Eclipse E400 microscope
(Nikon Instruments Inc., Melville, NY) at λex = 480 nm and λem = 530 nm. Images were
merged using the bundled software “Picture Frame” (Optronics, Goleta, CA). Images were
taken from multiple fields in at least three independent experiments and the number of
TUNEL-positive cells divided by the total number of counted cells was expressed as %
apoptotic death (mean ± SEM).
Data analysis
Data were analyzed using a one-way analysis of variance (ANOVA) with Tukey’s pair-wise
comparison test as a post hoc test using Prism 5.0b (GraphPad, La Jolla, CA).
RESULTS
Effect of substitution of Met35 by Nle or Val on Aβ oligomerization
A possible explanation of the different effects of substitution of Met35 by Nle or Val on Aβ
toxicity is that the substitutions have a profound effect on Aβ assembly. Though this would
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be unexpected given the similar hydrophobic nature of all three-side chains, we felt that it
was an important hypothesis to examine.
To test the effect of substituting Met35 by Nle or Val on the oligomer size distribution of Aβ,
the WT and substituted Aβ40 and Aβ42 analogues each were cross-linked using PICUP,
fractionated by SDS-PAGE and silver-stained (Fig. 1A). Uncross-linked WT and substituted
analogues of Aβ40 migrated as monomers, whereas Aβ42 analogues migrated as a
combination of monomer and a broad and smeary trimer/tetramer band (data not shown) as
described previously (Bitan et al. 2003a,Bitan et al. 2003b,Bitan et al. 2003c). Substitution
of Met35 by Nle or Val in Aβ40 had little effect on the oligomer size distributions obtained
using PICUP (Fig. 1A, B). All three peptides had comparable abundance of monomer
through trimer, followed by a lower abundance of tetramer band (Fig. 1A), similar to data
reported previously (Bitan et al. 2001,Bitan et al. 2003a).
Aβ42 analogues showed high abundance of pentameric and hexameric paranuclei as
described previously (Bitan et al. 2003a) (Fig. 1A). Substitution of Met35 by Nle or Val
yielded lower abundance of dimer and trimer and higher abundance of tetramer, pentamer,
and hexamer (Fig. 1A, C). These differences, particularly the decrease in dimer and increase
in tetramer abundance, were subtle for [Nle35]Aβ42 and more pronounced for [Val35]Aβ42.
Statistical analysis of densitometric data showed that the differences between WT Aβ42 and
[Val35]Aβ42 were statistically significant for monomer and all the oligomers except
heptamer (Fig. 1C). The difference between WT Aβ42 and [Nle35]Aβ42 was significant
only for dimer, trimer, and hexamer.
Effect of substitution of Met35 by Nle or Val on β-sheet formation
We used CD spectroscopy to study the effect of substituting Met35 by Nle or Val on
conformational changes during Aβ assembly (Fig. 2). In all cases except [Val35]Aβ42, the
initial spectrum was characterized by a minimum at 196–200 nm, suggesting that the peptide
conformation was predominantly a statistical coil (SC). With incubation, in all cases the
minimum at 196–200 nm was replaced by a maximum at 198–199 nm and, in the spectra of
Aβ42 analogues, was accompanied by formation of a minimum at 215–217 nm, which is
indicative of formation of β-sheet. A similar minimum typically is observed for Aβ40
analogues at higher peptide concentrations (Kirkitadze et al. 2001). We chose to keep the
concentration consistent across all assays and therefore did not observe the typical minimum
at 215 nm for Aβ40 analogues here.
Substitution of Met35 Nle slightly increased, whereas substitution by Val slightly decreased
the kinetics of conformational change in Aβ40. The kinetics of conformational transition in
[Nle35]Aβ42 was slightly increased relative to WT Aβ42, whereas β-sheet formation by
[Val35]Aβ42 was apparent already at the first time point (~5 min after dissolution) and was
faster than the kinetics of conformational change in [Nle35]Aβ42 or WT Aβ42 (Fig. 2).
These observations correlated with the trends observed in the PICUP experiments, i.e.,
higher abundance of larger oligomers correlates with faster kinetics of β-sheet formation.
Effect of substitution of Met35 by Nle or Val on assembly size
We used DLS to monitor the initial assembly size distribution of the Aβ analogues and the
progressive growth of aggregation size. In our experience, unlike Aβ42, which shows
formation of intermediate particle sizes during aggregation, in DLS experiments, Aβ40
initially shows only particles of RH ~1–2 nm and following incubation (typically ≥1 week),
very large particles appear, without accumulation of intermediate size particles (Bitan et al.
2003a). Based on this experience and because the effect of substitution by Nle or Val on
Aβ40 was found using PICUP or CD was relatively small, we did no expect DLS
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experiments with Aβ40 to add useful information and studied only Aβ42 analogues by DLS.
We measured both the change in particle size and the frequency of intensity spikes that
occur when very large particles cross the laser beam. For aggregating peptides, the
frequency of intensity spikes can be used to estimate the rate of fibril formation (Fradinger
et al. 2008).
Initially the WT and substituted Aβ42 analogues formed predominantly particles of
hydrodynamic radius (RH) =10–30 nm (Fig. 3) and no intensity spikes. This situation was
unchanged after 24 h of incubation and remained stable for several days. After 7 days, the
same distribution and no intensity spikes still were observed for WT Aβ42, whereas
particles of RH =100–200 nm appeared for both substituted analogues, which also displayed
occasional intensity spikes, indicating the beginning of fibril formation. By 14 days of
incubation, particles of RH =100–200 nm were observed also for WT Aβ42. At the same
time, particles of RH =1000–2000 nm were detected for the two substituted analogues. The
faster kinetics of [Nle35]Aβ42 and [Val35]Aβ42 relative to WT Aβ42 correlated with the
PICUP and CD data.
It is important to note that because in DLS measurements the intensity is proportional to the
square of the mass, the populations of larger particles are highly overrepresented in Fig. 3.
Particles of RH =10–15 nm still existed at all time points in all cases but they were
overshadowed by the intensity of larger particles.
The overall slower kinetics of aggregation in the DLS experiments compared to CD and EM
(see below) reflects the different preparation and incubation conditions. Samples measured
by DLS must be filtered to remove dust particles and are incubated without agitation.
Without these measures, large particles render the measurements useless already at the very
early time points.
Effect of substitution of Met35 by Nle or Val on morphology
The morphology of the WT and substituted peptides was examined by EM immediately after
preparation and after 72 h (Aβ40) or 24 h (Aβ42) of incubation (Fig 4). All the peptides
initially had non-fibrillar morphology and showed structures consistent with oligomers.
Following 72 h of incubation, the morphology of Aβ40 and [Nle35]Aβ40 did not change.
The behavior of [Val35]Aβ40 was less consistent. In a some experiments, this peptide
showed mixture of oligomers and fibrils whereas in others its morphology was similar to
Aβ40 and [Nle35]Aβ40 (Fig 4). Aβ42 and both its substituted analogues showed abundant
fibrils after 24 h of incubation. Quasi-spherical oligomers still could be observed in all cases
(Fig 4). Taken together, the results of most of the biophysical experiments show that
substitution of Met by Nle or Val increases the tendency of Aβ to self-assemble. This
tendency correlates with the higher hydrophobicity of Nle and Val relative to Met.
Effect of substitution of Met35 by Nle or Val on Aβ neurotoxicity
To study the structure–activity relationships of substituted Aβ analogues, we treated rat
primary cortical or hippocampal neurons with WT, Nle-, or Val-substituted Aβ40 or Aβ42
and measured neurotoxicity using the MTT reduction, LDH release, and TUNEL staining
assays. We used these three different assays because each measures a different aspect of cell
viability: The MTT assay measures mitochondrial activity of viable cells (Wang et al. 2006),
the LDH assay signifies membrane integrity and is a direct measurement of cell death
(Decker & Lohmann-Matthes 1988), and the TUNEL assay indicates DNA fragmentation
and denotes apoptosis.
Because Aβ42 is substantially more toxic than Aβ40, we performed full dose-response
analysis (at 1–100 µM) for Aβ42 analogues using both the MTT and LDH assays, whereas
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the toxicity of Aβ40 analogues was assessed at a single concentration—10 µM, for
comparison with Aβ42 analogues and to facilitate correlating the data with the results of the
biophysical measurements described above.
Using the MTT assay, the concentration at which 50% of the maximal toxicity (EC50) was
observed were 10±2 µM, 11±3, and 9±1 fo r Aβ42, [Nle35]Aβ42, and [Val35]Aβ42,
respectively (Fig. 5A). The EC50 values measured using the LDH assay were 11±5, 11±5,
and 12±8 for Aβ42, [Nle35]Aβ42, and [Val35]Aβ42, respectively (Fig 5B). Comparison of
the neurotoxicity at 10 µM showed that the toxicity of the substituted analogues was similar
to that of the WT peptides for both Aβ40 and Aβ42 alloforms using both the MTT (Fig. 5C)
and LDH (Fig 5D) assays. In all cases, the only statistically significant differences were
found between Aβ42 and Aβ40 analogues, whereas the differences between the substituted
analogues and the corresponding WT Aβ alloforms were small and statistically insignificant.
Cortical and hippocampal neurons showed similar sensitivity to Aβ analogues in most
experiments.
Similar results were obtained using the TUNEL assay, which showed that all the Aβ
analogues induced apoptosis. Aβ42 analogues were significantly more toxic that Aβ40
analogues yet no significant differences were found between the Nle- or Val-substituted
analogues and the WT peptides (Fig 6).
DISCUSSION
Substitution of Met35 in Aβ by redox-unreactive, aliphatic groups has been reported to both
decrease, in the case of Nle (Varadarajan et al. 1999, Butterfield & Boyd-Kimball 2005,
Clementi et al. 2006, Piacentini et al. 2008), and increase, in case of Val (Ciccotosto et al.
2004) Aβ neurotoxicity, with no satisfactory explanation for these contradictory
observations. The toxicity findings also were not correlated directly with the assembly
properties of the substituted analogues. To re-evaluate these data, we compared the Nle- and
Val-substituted and WT analogues of both Aβ40 and Aβ42 using multiple biophysical and
cytotoxicity assays.
Using four different biophysical assays, we found that substituting Met35 by Nle or Val
tended to increase Aβ assembly. The substitutions effect on the oligomer size distribution
(Fig. 1A) or conformational change kinetics (Fig. 2) of Aβ40 was modest relative to the
effect on Aβ42. In particular, substitution of Met35 by Val was found to accelerate the
aggregation kinetics of Aβ42 (Figs. 2 and 3), which correlated with a shift in the oligomer
size distribution towards higher order oligomers (Fig. 1B, C). A similar, yet more subtle
effect on acceleration of aggregation (Fig. 3) and a shift in oligomer size distribution (Fig.
1C) was observed for [Nle35]Aβ42. Overall, the tendency to increase self-assembly was
more pronounced in Aβ42 than in Aβ40 and correlated with the somewhat higher
hydrophobicity of Nle and Val relative to Met. These data support a central role for the C-
terminus in the assembly of Aβ42 and less so for Aβ40, in agreement with previous reports
(Bitan et al. 2003a,Urbanc et al. 2004,Yun et al. 2007,Yang & Teplow 2008,Bernstein et al.
2009). We note that the DLS data obtained for the Aβ42 analogues are comparable
qualitatively but not quantitatively with the CD results due to the differences in samples
preparation. Using different preparation protocols was necessary because of the fundamental
differences between the two methods. Unlike CD, which is an averaging technique, DLS
overemphasizes large particles, as discussed above. Therefore, DLS samples must be filtered
prior to measurement to exclude dust particles and cannot be agitated because formation of
even a few large particles due to agitation would lead to skewed results. Nevertheless, the
capability of DLS to measure assembly dynamics non-invasively and with high sensitivity
provides useful, complementary information to the CD and EM measurements.
Maiti et al. Page 8
J Neurochem. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The correlation we observed between formation of higher order oligomers and increased β-
sheet formation concords with recent data showing a similar correlation in isolated Aβ40
oligomers (Ono et al. 2009). These data also are in agreement with the acceleration of β-
sheet formation by [Val35]Aβ42 compared to WT Aβ42 in the presence of lipid vesicles and
Cu2+ ions observed by Ciccotosto et al. using CD (Ciccotosto et al. 2004). Compared to the
latter study, our data reveal that the faster conformational transition of the Val-substituted
peptide likely results from the substitution itself rather than from presence of vesicles or
Cu2+ ions.
Whereas Ciccotosto et al., (2004) reported that at 5 µM both Aβ42 and [Val35]Aβ42 showed
non-fibrillar morphology both initially and after 72 h of incubation at 37°C (Ciccotosto et al.
2004), we found fibrillar morphology for all three Aβ42 analogues after 24 h of incubation.
These morphological variations likely result from the difference in experimental setup. We
used 10 µM concentration and incubated the peptides at 25°C with continuous agitation,
whereas Ciccotosto et al. used 5 µM and incubated at 37°C without agitation.
Despite the differences in assembly kinetics and in contrast to previous reports, we found
very similar levels of toxicity for the WT and substituted analogues of both Aβ40 and Aβ42
using three different assays, MTT, LDH, and TUNEL, in both cortical and hippocampal
primary neurons.
Dose-response analysis for Aβ42 and its analogues showed nearly identical values in both
the MTT and LDH assays (Fig. 5). When the toxicity of Aβ40 and Aβ42 analogues
measured by all three assays was compared at 10 µM, the same concentration used in the
biophysical studies, the only significant difference found was between the Aβ40 and Aβ42
groups, but not among the WT and substituted analogues within each group (Figs. 5 and 6).
Differences in experimental settings likely explain the difference between our data and those
reported by other groups. One obvious possibility is the source of the peptides used.
However, in our experience, the differences in biophysical and biological behavior between
Aβ analogues prepared by the UCLA Biopolymers Laboratory and those from commercial
sources are not bigger than typical batch-to-batch variation. Moreover the toxicity of WT Aβ
in our study was comparable that observed by the other laboratories (Ciccotosto et al. 2004,
Yatin et al. 1999, Varadarajan et al. 1999), suggesting that the peptide source did not
contribute significantly to the observed results.
More likely explanations include differences in the peptide preparation methods and cell
types used. For example, Varadarajan et al., used [Nle35]Aβ40 that was pre-incubated for 24
h before addition to culture and measured the effect of this peptide after 6 h of incubation
with cells (Varadarajan et al. 1999). Similarly, Yatin et al., used [Nle35]Aβ42, which was
dissolved in water at 1 mg/mL, and incubated for 24 h before addition to cells (Yatin et al.
1999). In neither case were the peptides treated to remove aggregates prior to their
dissolution. In contrast, we treated all the peptides with HFIP to obtain aggregate-free
starting conditions, prepared solutions in cell culture media, and added these solutions to the
cells immediately after preparation. It is therefore plausible that we observed toxicity of
[Nle35]Aβ oligomers, which likely were not present in the former studies because of the 24 h
pre-incubation step.
In different studies, Clementi et al. (Clementi et al. 2006) and Piacentini et al. (Piacentini et
al. 2008) found little or no toxicity for [Nle35]Aβ42 using IMR-32 cells. Though neither
group used a pre-incubation step, they diluted the peptides from stock solutions prepared in
DMSO directly into the cell culture medium. Thus, the differences between their results and
the ones presented here may stem both from the higher sensitivity of primary neurons to Aβ-
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induced toxicity relative to IMR-32 cells and from the differences in the preparation
protocols used.
The higher toxicity of [Val35]Aβ42 relative to WT Aβ42 reported by Ciccotosto et al.
(Ciccotosto et al. 2004), which we did not observe, also may be due to differences in
experimental protocols. They prepared their peptides without HFIP treatment and adjusted
the concentration based on measurement of absorbance at 214 nm, a method we found to
produce results that are inconsistent with amino acid analysis data (G. Bitan, unpublished
results).
Ciccotosto et al. suggested that [Val35]Aβ42 has higher affinity for lipid membranes than
Aβ42, which may be linked to increased toxicity, although both Aβ42 and [Val35]Aβ42
were reported to produce similar amount of H2O2 (Ciccotosto et al. 2004). A different view
was suggested by Murray et al., who found that substitution of Met35 by Val decreased lipid
peroxidation (Murray et al. 2005). Because we did not study lipid peroxidation, our data are
not directly comparable with those of Murray et al. Nevertheless, our results suggest that the
presence of Met35 in Aβ is not an important factor in Aβ-induced toxicity.
Our conclusion is consistent with a recent elegant study by Butterfield et al. (Butterfield et
al. 2009) who used a variant of the PDAPP transgenic mouse model of AD (Masliah et al.
1996), containing an M631L mutation in the amyloid β-protein precursor-encoding gene,
which leads to substitution of Met35 in Aβ by Leu. The study showed that Met35 was
required for observation of markers of oxidative stress, such as protein carbonylation and
lipid peroxidation in the brains of the mice, yet the substitution of Met35 by Leu had no
effect on the learning and memory impairment of the mice assessed using the Morris Water
Maze (Butterfield et al. 2009). The reasons for this apparent discrepancy are not understood
and may be related to differences in deposition patterns between WT and [Leu35]Aβ or to
involvement of toxic APP fragments other than Aβ, as suggested by the authors (Butterfield
et al. 2009). As is the case with most mouse models of AD, the impairment of learning and
memory observed by Butterfield et al. was not associated with neuronal loss (Morrissette et
al. 2009). Nonetheless, if one accepts the assumption that the results of the learning and
memory tests measured in vivo correlate with our neurotoxicity measurements in primary
cultures, these results support our conclusion that the presence of Met35 is not important for
Aβ toxicity.
Abbreviations
AD Alzheimer’s disease
Aβ amyloid β-protein
APS ammonium persulfate
BrdU 5-bromo-2-deoxyuridine
CD circular dichroism spectroscopy
DMEM Dulbecco’s modified Eagle’s medium
DLS dynamic light scattering
EM electron microscopy
HFIP 1,1,1,3,3,3-hexafluoroisopropanol
LDH lactate dehydrogenase
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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OD optical density
PICUP photo-induced cross-linking of unmodified proteins
ROS reactive oxygen species
Ru(Bpy) tris(2,2’-bipyridyl)ruthenium dichloride
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
TUNEL terminal deoxyribonucleotidyl transferase dUTP nick end labeling
WT wild-type
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Fig. 1. Oligomer size distribution of Aβ analogues
Peptides were cross-linked using PICUP immediately after preparation, fractionated by
SDS-PAGE, and the gels silver-stained. A) A representative gel showing the oligomer size
distribution of each analogue. The migration of molecular weight markers is shown on the
left. B) Relative band abundance of cross-linked Aβ40 analogues. C) Relative band
abundance of cross-linked Aβ42 analogues. The relative abundance of each band was
calculated as a percentage of the entire lane. The data in panels B and C are an average of 6
independent experiments. Statistical significance: * p<0.05, ** p<0.01, and ***p<0.001
applicable to all figures.
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Fig. 2. Conformational change kinetics of Aβ analogues
Aβ40, Aβ42, and their Nle35- or Val35-substituted analogues were incubated at 25°C with
agitation and the solutions monitored periodically by CD spectroscopy. Aβ40 analogues
were measured up to 72 h and Aβ42 analogues up to 24 h. The spectra are representative of
three independent experiments.
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Fig. 3. Particle size growth Aβ analogues
Aβ42 and its Nle35- and Val35-substituted analogues were filtered through a 20-nm pore size
filter, incubated at 25°C under quiescent conditions and monitored by DLS for up to 14
days.
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Fig. 4. Time-dependent morphological change in Aβ analogues
Aβ analogues were incubated at 25°C for 72 h (Aβ40) or 24 h (Aβ42) with agitation.
Aliquots were spotted at the beginning and end of the measurement on glow-discharged,
carbon-coated grids, stained with uranyl acetate, and examined by EM. The images are
representative of three independent experiments. The scale bars indicate 100 nm and are
applicable to all images.
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Fig. 5. Aβ-induced neurotoxicity measured by the MTT and LDH assays
Rat primary cortical or hippocampal neurons were treated with Aβ40, Aβ42, or their Nle35-
or Val35-substituted analogues for 48 h. Cell viability was assayed by measuring MTT
reduction by active cells or by LDH release. A) Dose–response analysis of Aβ42 analogues
by the MTT assay in cortical neuron. B) Dose–response analysis of Aβ42 analogues by the
LDH assay in cortical neuron. C) Cell viability following treatment with 10 µM of each
peptide measured by the MTT assay in cortical neurons. D) Cell viability following
treatment with 10 µM of each peptide measured by the LDH assay in cortical neurons. E)
Cell viability following treatment with 10 µM of each peptide measured by the MTT assay
in hippocampal neurons. F) Cell viability following treatment with 10 µM of each peptide
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measured by the LDH assay in hippocampal neurons. The data are average of three
independent experiments with 6 data points per condition (n=18). *p<0.05, **p<0.01, and
***p<0.001 vs the corresponding Aβ40 analogue.
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Fig. 6. Aβ-induced neuronal apoptosis
Rat primary cortical neurons were grown for 6 days on poly-D-lysine-coated cover slips and
then treated with 10 µM of each Aβ analogue for 48 h. DNA fragmentation was probed
using APO-BrdU staining. Micrographs are representative of 10–15 different fields of each
experiment. Arrows indicate TUNEL-positive cells. The number of apoptotic cells divided
by the total number of cells (counted manually) is expressed as % apoptotic death. The data
are representative of three independent experiments. **p<0.01 and ***p<0.001 vs control.
Maiti et al. Page 21
J Neurochem. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
